In order to reduce on-target/off-tumor reactions and to increase the specificity of the RevCAR T-cell response towards AML blasts, we aimed to establish RevCAR T-cells for a programmable combinatorial targeting of AML blasts co-expressing CD33 and CD123. The gene discussed is CD33; the disease is neoplasm.